Policy & Regulation
Ipsen agrees to acquire Epizyme
27 June 2022 -

Biopharmaceutical companies Ipsen (Euronext:IPN) and Epizyme (Nasdaq:EPZM) announced on Monday a definitive merger agreement under which Ipsen will acquire Epizyme for USD1.45 per share plus a contingent value right (CVR) of USD1.00 per share.

The primary focus of the acquisition is Epizyme's lead product Tazverik (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor which has been approved by the US Food and Drug Administration (FDA). It is currently indicated for adults with relapsed or refractory follicular lymphoma (FL) whose tumours are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies, and for adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options, as well as for adults and paediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

Ipsen will also acquire Epizyme's first-in-class, oral SETD2 inhibitor development candidate, EZM0414, which was granted FDA Fast Track status and is currently under evaluation in a Phase I/Ib trial in adult patients with relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma, as well as a portfolio of preclinical programmes focusing on epigenetic targets.

The acquisition is anticipated to close by the end of the third quarter of 2022.